The 10 Most Heavily Shorted Bio-Pharma Stocks

The 10 biotech and drug stocks with the largest short interest as percentage of float, according to S&P CapitalIQ:

10. Spectrum Pharmaceuticals (SPPI) (26.8% shares short)

^NBI Chart
^NBI data by YCharts

9. Dendreon (DNDN) (29.6% shares short)

DNDN Chart
DNDN data by YCharts

8. Achillion Pharma (ACHN) (29.7% shares short)

^NBI Chart
^NBI data by YCharts

7. Arena Pharmaceuticals (ARNA) (29.9% shares short)

ARNA Chart
ARNA data by YCharts

6. Ziopharm (ZIOP) (30.9% shares short)

ZIOP Chart
ZIOP data by YCharts

5. Intrexon (XON) (32.8% shares short)

XON Chart
XON data by YCharts

4. Idenix Pharma (IDIX) (33.3% shares short)

IDIX Chart
IDIX data by YCharts

3. Synta Pharma (SNTA) (36.4% shares short)

SNTA Chart
SNTA data by YCharts

2. Sarepta Therapeutics (SRPT) (39% shares short)

SRPT Chart
SRPT data by YCharts

1. Myriad Genetics (MYGN) (52.4% shares short)

MYGN Chart
MYGN data by YCharts

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug